Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer

MLA

N. Schleucher, et al. “Extended Phase I Study of Capecitabine and Weekly Irinotecan as First-Line Chemotherapy in Metastatic Colorectal Cancer.” European Journal of Cancer, vol. 37, Apr. 2001, pp. S290–91. EBSCOhost, https://doi.org/10.1016/s0959-8049(01)81564-1.

APA

N. Schleucher, Siegfried Seeber, Wolf Achterrath, Mitra Tewes, Youcef M. Rustum, U. Vanhoefer, Hansjochen Wilke, Stephan Frings, Andreas Harstrick, & S. Cao. (2001). Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer. European Journal of Cancer, 37, S290–S291. https://doi.org/10.1016/s0959-8049(01)81564-1

Chicago

N. Schleucher, Siegfried Seeber, Wolf Achterrath, Mitra Tewes, Youcef M. Rustum, U. Vanhoefer, Hansjochen Wilke, Stephan Frings, Andreas Harstrick, and S. Cao. 2001. “Extended Phase I Study of Capecitabine and Weekly Irinotecan as First-Line Chemotherapy in Metastatic Colorectal Cancer.” European Journal of Cancer 37 (April): S290–91. doi:10.1016/s0959-8049(01)81564-1.